Our 2.5-hour interactive program, intentionally created for Community Oncology Nurses, focused on antibody drug conjugates (ADCs) providing an overview of recent clinical trial data that drives treatment decisions as well as case-based discussion of management of treatment-related side effects. Guidance on the utilization and incorporation of bispecific antibodies into community oncology was also discussed with key takeaways highlighted. Consistent with our mission to provide value to independent community oncology practices, Cornerstone Specialty Network offers this innovative and interactive forum that bridges the gap between academic conference data and how it is applied to community oncology practice.
This program is not CME accredited.
